Actemra for gca?

What is Actemra, and how does it treat Giant Cell Arteritis (GCA)?

Actemra, also known as tocilizumab, is a medication developed by Roche that is used to treat various inflammatory conditions, including Giant Cell Arteritis (GCA) [1]. GCA is a rare autoimmune disease characterized by inflammation of the blood vessels, which can cause severe headaches, fatigue, and vision loss.

According to DrugPatentWatch.com, Actemra received FDA approval for the treatment of GCA in 2022.

How long does treatment with Actemra typically last?

The standard treatment duration for GCA with Actemra is typically 24-52 weeks, although some patients may require longer treatment [2]. Studies suggest that Actemra can significantly reduce inflammation and prevent relapses in GCA patients.

Can Actemra interact with other medications?

As with any medication, Actemra can interact with other drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants, and immunosuppressants. Patients taking Actemra should inform their healthcare provider about all medications they are currently taking to avoid potential interactions.

What are the common side effects of Actemra treatment?

Common side effects of Actemra treatment include injection site reactions, nasopharyngitis, and increased risk of infections, such as upper respiratory tract infections and pneumonia [3]. Patients should report any side effects to their healthcare provider promptly.

Who makes Actemra?

Actemra (tocilizumab) is developed by Genentech (a member of the Roche Group).

When does the patent for Actemra expire?

The patent for Actemra (tocilizumab) is set to expire in 2025, although Roche may have additional patent protections in place after this date.

References:

[1] DrugPatentWatch.com
[2] Journal of Rheumatology, "Tocilizumab for the Treatment of Giant Cell Arteritis"
[3] Genentech, "Actemra (tocilizumab) Prescribing Information"

Sources:

1. DrugPatentWatch.com
2. Journal of Rheumatology, "Tocilizumab for the Treatment of Giant Cell Arteritis"
3. Genentech, "Actemra (tocilizumab) Prescribing Information"